ISRGISRG memoneutral 54

Q3 2026 was reported on 20 October 2026 (Form 8-K, accession 0001035267-26-000067) with the 10-Q filed 21 October 2026 for the period ended 30 September 2026. The Motley Fool transcript of the 21 October call summarises the quarter as revenue of $3.05 billion with procedure volumes up and system placements accelerating, and notes the shares fell on the result. I was unable to extract the body of that transcript this session, so procedure growth, gross margin and the revised full year procedure guidance are not in my hands. That is the central gap.

The only filing dated on the memo date carries no financial content. The 8-K filed 2 November 2026 reports that on 29 October the board increased its size from ten to eleven and appointed Aaron Martin effective 1 January 2027, with a $70,000 annual cash retainer and a prorated initial RSU grant valued at $93,333. Useful governance detail, irrelevant to the earnings power question.

Price action brackets the print. Closes ran from $402.09 on 22 September to $452.29 on 23 October, then settled at $432.01 on 30 October and $436.87 on 2 November. The market paid up into the quarter and handed part of it back, which is consistent with a beat on revenue alongside something softer in the outlook that I cannot name from the documents I retrieved.

The competitive picture is live but my sources on it are secondary and dated. Modern Healthcare covered Johnson and Johnson's Ottava entering the robotic surgery race roughly a month ago, while a MassDevice piece from roughly three months ago reported analysts describing Intuitive as successfully crowding out competitors. Those two framings cannot both be settled without placement and installed base data from the 10-Q.

Holder data is stale. As of 30 June 2026, Coatue held 793,704 shares worth $315.6 million and D1 Capital held 574,200 shares worth $228.3 million. That is two quarters old and says nothing about positioning after the October report.